Which novel HER2 agents are under evaluation for the treatment of breast cancer?

Updated: May 14, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Karl S Roth, MD  more...
  • Print


Novel HER2 agents under evaluation include the following:

  • Amrubicin

  • Dasatinib

  • HER2 chimeric receptor and TGF-beta dominant negative receptor expressing EBV-specific lymphocytes

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!